Crizotinib treatment of EML4-ALK-positive advanced non-small cell lung cancer translational research
Echinoderm microtubule-associated protein-like 4 (echinoderm microtubule associated protein like 4, EML4) anaplastic lymphoma kinase (anaplasticlymphoma kinase, ALK) fusion gene (EML4-ALK) is driven in recent years, newly discovered cancer genes, the fusion gene positive non-small cell lung cancer (non-smallcell lung cancer, NSCLC) patients have unique clinical features, may be associated with epidermal growth factor receptor (epidermal growth factor receptor, EGFR) tyrosine kinase inhibitors (tyrosine kinase inhibitor, TKI) drug-related. EML4-ALK mutations for new targeted drugs --- ALK inhibitor crizotinib, now has entered Phase Ⅲ clinical trials. Stage Ⅰ and Ⅱ clinical trials have confirmed, crizotinib treatment of EML4-ALK-positive advanced NSCLC patients effectively, can improve the symptoms of cancer patients, progression-free survival of patients (progression free survival, PFS) extension, the overall response rate (overall response rate, ORR) increased. And the toxic effects of crizotinib smaller compared with conventional chemotherapy, patients tolerated. Like other TKI, crizotinib also acquired resistance phenomenon, its resistance mechanism needs further study. In this paper, crizotinib from basic research to the treatment of EML4-ALK-positive advanced NSCLC patients into clinical applications for a review process.
Crizotinib treatment of EML4-ALK-positive advanced non-small cell lung cancer translational research
ReplyDeleteEchinoderm microtubule-associated protein-like 4 (echinoderm microtubule associated protein like 4, EML4) anaplastic lymphoma kinase (anaplasticlymphoma kinase, ALK) fusion gene (EML4-ALK) is driven in recent years, newly discovered cancer genes, the fusion gene positive non-small cell lung cancer (non-smallcell lung cancer, NSCLC) patients have unique clinical features, may be associated with epidermal growth factor receptor (epidermal growth factor receptor, EGFR) tyrosine kinase inhibitors (tyrosine kinase inhibitor, TKI) drug-related. EML4-ALK mutations for new targeted drugs --- ALK inhibitor crizotinib, now has entered Phase Ⅲ clinical trials. Stage Ⅰ and Ⅱ clinical trials have confirmed, crizotinib treatment of EML4-ALK-positive advanced NSCLC patients effectively, can improve the symptoms of cancer patients, progression-free survival of patients (progression free survival, PFS) extension, the overall response rate (overall response rate, ORR) increased. And the toxic effects of crizotinib smaller compared with conventional chemotherapy, patients tolerated. Like other TKI, crizotinib also acquired resistance phenomenon, its resistance mechanism needs further study. In this paper, crizotinib from basic research to the treatment of EML4-ALK-positive advanced NSCLC patients into clinical applications for a review process.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Enzalutamide
TOK-001
Anastrozole
GSK1292263
TAK-875
Andarine
Maraviroc
Dolutegravir
Elvitegravir
HIV-1 integrase inhibitor 2